All PlansAdministrativeMedium impact
Voluntary nationwide recall: Zenzedi (Azurity - January)
UPMC Health Plan·Psychiatry, Neurology, Sleep Medicine +2 more·Pharmacy
Effective date
Jan 24, 2024
We identified it
Aug 7, 2026
Summary
Azurity Pharmaceuticals has issued a voluntary nationwide recall of one lot of Zenzedi (amphetamine) 30 mg tablets due to contamination with Carbinoxamine Maleate (an antihistamine). Patients may have received the wrong medication, risking undertreatment of ADHD/narcolepsy and potential adverse events. Billing teams should be aware that affected patients may file claims for medication replacement or adverse event treatment related to this recall.
Action Required
Immediately: Notify providers and clinical staff of the Zenzedi recall lot to identify affected patients in your practice. Flag any patient records indicating Zenzedi 30 mg dispensing around the recall date. Be prepared to process claims for: (1) replacement medication once patients obtain correct Zenzedi from pharmacy, and (2) any related medical visits for adverse event management if patients took Carbinoxamine. Coordinate with your pharmacy partners to cross-reference recalled lot numbers with your patient population. Ensure billing staff can document the reason for any duplicate or replacement medication claims related to this recall. Monitor for increased claims activity related to ADHD/narcolepsy management during the recall resolution period.